LLYEli Lilly
$1255.40+0.88%Real quote · delayedPharma🏛️ Company factsSEC filings + FINRA official data
Annual revenue $65.2B · latest quarter up 47.7% YoY · profitable (FY net income $20.6B) · short activity above its recent average — bears adding.
FY revenue
$65.2B
2025-12
Latest Q YoY
+47.7%
FY net income
$20.6B
Diluted EPS
$23
Short volume
50.9%
20d avg 41.4% · shorts building
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-07-23passive (13G)LILLY ENDOWMENT INC
- 2026-05-01passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability Medium · 61/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$8.38 vs $6.01+39.43%
- Mar 2026$8.55 vs $7.06+21.1%
- Dec 2025$7.54 vs $6.99+7.87%
- Sep 2025$7.02 vs $6.02+16.61%
This company habitually beats by +21.3% — the next report has to clear that bar to count as good news.
Analyst estimates, not our forecast · not investment advice
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · dot = engine's call · color = outcome, arrow = direction
📜 Call history (newest first
36 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →